Mutual of America Capital Management LLC Reduces Stock Position in Vericel Corporation $VCEL

Mutual of America Capital Management LLC reduced its holdings in shares of Vericel Corporation (NASDAQ:VCEL) by 8.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 153,609 shares of the biotechnology company’s stock after selling 14,798 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Vericel were worth $4,834,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Ameritas Advisory Services LLC acquired a new stake in Vericel in the second quarter valued at $30,000. CWM LLC increased its position in shares of Vericel by 101.3% in the 2nd quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 694 shares during the last quarter. AlphaQuest LLC acquired a new stake in shares of Vericel in the 2nd quarter valued at about $60,000. Osaic Holdings Inc. lifted its position in shares of Vericel by 13.7% during the second quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 353 shares during the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in Vericel by 178.4% in the second quarter. Smartleaf Asset Management LLC now owns 3,241 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 2,077 shares in the last quarter.

Vericel Trading Up 0.8%

Shares of Vericel stock opened at $36.50 on Friday. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of 152.09 and a beta of 1.17. Vericel Corporation has a twelve month low of $29.24 and a twelve month high of $63.00. The business’s 50 day simple moving average is $37.69 and its 200-day simple moving average is $36.29.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.12. Vericel had a return on equity of 4.30% and a net margin of 5.06%.The firm had revenue of $67.50 million during the quarter, compared to the consensus estimate of $64.57 million. During the same period in the prior year, the business earned ($0.02) EPS. The firm’s revenue was up 16.6% on a year-over-year basis. Sell-side analysts predict that Vericel Corporation will post 0.14 earnings per share for the current year.

Analyst Ratings Changes

VCEL has been the topic of several research reports. Truist Financial cut their price objective on Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Zacks Research downgraded Vericel from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a research report on Sunday, January 25th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Vericel in a report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.